Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Methods in Molecular Biology (Clifton, N.J.)|September 6, 2019
Evaluation of Oncolytic Virus-Induced Therapeutic Tumor Vaccination Effects in Murine Tumor ModelsRūta Veinalde
Biotechnology and Applied Biochemistry|August 15, 2013
Ex vivo cytokine production in peripheral blood mononuclear cells after their stimulation with dsRNA of natural originRūta Veinalde, Ramona Petrovska, Rūta Brūvere, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2018
Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid TumorsTobias Speck, Johannes P W Heidbuechel, Rūta Veinalde, et al.
Melanoma Research|April 3, 2013
Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutationRūta Veinalde, Aija Ozola, Kristīne Azarjana, et al.
Molecular Therapy Oncolytics|January 3, 2022
Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memoryRūta Veinalde, Gemma Pidelaserra-Martí, Coline Moulin, et al.
The Journal of General Virology|August 16, 2017
A Tupaia paramyxovirus vector system for targeting and transgene expressionChristine E Engeland, Sascha Bossow, Andrew W Hudacek, et al.
Oncoimmunology|May 17, 2017
Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activationRūta Veinalde, Christian Grossardt, Laura Hartmann, et al.
Viruses|October 19, 2019
Immunological Effects and Viral Gene Expression Determine the Efficacy of Oncolytic Measles Vaccines Encoding IL-12 or IL-15 AgonistsPaul S Backhaus, Rūta Veinalde, Laura Hartmann, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 27, 2014
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapyChristine E Engeland, Christian Grossardt, Rūta Veinalde, et al.
Frontiers in Immunology|February 2, 2023
Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC modelRūta Veinalde, Gemma Pidelaserra-Martí, Coline Moulin, et al.
Pageof 1